Index S&P 500
P/E 14.24
EPS (ttm) 1.72
Insider Own 0.12%
Shs Outstand 5.69B
Perf Week -0.89%
Market Cap 138.90B
Forward P/E 7.79
EPS next Y 3.14
Insider Trans 0.00%
Shs Float 5.68B
Perf Month -3.21%
Enterprise Value 185.92B
PEG -
EPS next Q 0.65
Inst Own 66.79%
Short Float 2.06%
Perf Quarter -0.61%
Income 9.80B
P/S 2.21
EPS this Y 0.84%
Inst Trans -0.95%
Short Ratio 2.07
Perf Half Y 9.65%
Sales 62.78B
P/B 1.50
EPS next Y 0.04%
ROA 4.58%
Short Interest 116.82M
Perf YTD -7.92%
Book/sh 16.32
P/C 9.27
EPS next 5Y -0.62%
ROE 10.59%
52W High 27.69 -11.77%
Perf Year -12.72%
Cash/sh 2.64
P/FCF 13.39
EPS past 3/5Y -28.69% -13.27%
ROIC 6.52%
52W Low 20.92 16.81%
Perf 3Y -48.10%
Dividend Est. 1.70 (6.95% )
EV/EBITDA 7.11
Sales past 3/5Y -7.84% 9.10%
Gross Margin 69.12%
Volatility 2.44% 1.75%
Perf 5Y -28.85%
Dividend TTM 1.72 (7.04% )
EV/Sales 2.96
EPS Y/Y TTM 128.96%
Oper. Margin 30.99%
ATR (14) 0.52
Perf 10Y -23.78%
Dividend Ex-Date Nov 07, 2025
Quick Ratio 0.97
Sales Y/Y TTM 4.44%
Profit Margin 15.60%
RSI (14) 45.93
Recom 2.46
Dividend Gr. 3/5Y 2.49% 2.97%
Current Ratio 1.28
EPS Q/Q -20.96%
SMA20 -0.57%
Beta 0.42
Target Price 28.61
Payout 120.11%
Debt/Eq 0.66
Sales Q/Q -5.92%
SMA50 -1.26%
Rel Volume 2.08
Prev Close 24.85
Employees 81000
LT Debt/Eq 0.62
Earnings Nov 04 BMO
SMA200 -0.79%
Avg Volume 56.50M
Price 24.43
IPO Jan 17, 1944
Option/Short Yes / Yes
EPS/Sales Surpr. 37.53% 0.94%
Trades
Volume 117,645,635
Change -1.69%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-22-25 Initiated
Cantor Fitzgerald
Neutral
$24
Dec-10-24 Resumed
BofA Securities
Neutral
$29
Nov-15-24 Initiated
Wolfe Research
Underperform
$25
Oct-25-24 Resumed
Citigroup
Neutral
$30
Oct-17-24 Initiated
Bernstein
Mkt Perform
$32
Aug-07-24 Upgrade
Daiwa Securities
Neutral → Outperform
Mar-22-24 Downgrade
Argus
Buy → Hold
Feb-23-24 Initiated
Guggenheim
Buy
$36
Jan-04-24 Downgrade
TD Cowen
Outperform → Market Perform
$32
Oct-20-23 Resumed
UBS
Neutral
$36 → $34
Oct-16-23 Upgrade
Jefferies
Hold → Buy
$38 → $39
Jul-17-23 Reiterated
JP Morgan
Neutral
$45 → $41
Jul-14-23 Initiated
HSBC Securities
Buy
$50
Jun-29-23 Downgrade
Credit Suisse
Outperform → Neutral
$47 → $40
May-11-23 Downgrade
Daiwa Securities
Outperform → Neutral
$38
Mar-06-23 Initiated
Jefferies
Hold
$43
Feb-07-23 Upgrade
Daiwa Securities
Neutral → Outperform
$51
Jan-26-23 Downgrade
UBS
Buy → Neutral
$55 → $47
Jan-17-23 Downgrade
Wells Fargo
Overweight → Equal Weight
$54 → $50
Jan-04-23 Downgrade
BofA Securities
Buy → Neutral
$60
Show Previous Ratings
Nov-07-25 10:50PM
(The Wall Street Journal)
10:07PM
(The Wall Street Journal)
02:10PM
01:02PM
11:46AM
11:28AM
Loading…
11:28AM
11:22AM
(Investor's Business Daily)
11:11AM
10:44AM
08:20AM
08:20AM
08:16AM
08:13AM
05:30AM
(The Wall Street Journal)
Nov-06-25 10:21PM
05:30PM
Loading…
05:30PM
04:40PM
03:33PM
03:23PM
03:03PM
(The Wall Street Journal)
03:02PM
02:20PM
01:34PM
12:36PM
12:05PM
11:58AM
11:45AM
11:16AM
10:46AM
10:14AM
(Investor's Business Daily)
08:09AM
Loading…
08:09AM
07:51AM
07:29AM
04:44AM
04:10AM
Nov-05-25 06:13PM
05:08PM
04:52PM
(The Wall Street Journal)
04:33PM
04:33PM
04:31PM
(Investor's Business Daily)
04:15PM
03:54PM
02:02PM
11:41AM
10:43AM
(The Wall Street Journal)
10:43AM
08:19AM
06:52AM
(Pharmaceutical Technology)
06:48AM
06:47AM
05:00AM
03:06AM
02:22AM
12:32AM
12:00AM
(Associated Press Finance)
12:00AM
(Associated Press Finance)
Nov-04-25 11:31PM
06:52PM
06:45PM
(The Wall Street Journal)
05:10PM
(The Wall Street Journal)
04:51PM
04:30PM
04:27PM
04:18PM
(Investor's Business Daily)
04:15PM
04:14PM
04:12PM
(Investor's Business Daily)
02:39PM
01:51PM
01:09PM
12:59PM
12:26PM
11:18AM
11:15AM
10:59AM
10:54AM
10:47AM
(Investor's Business Daily)
10:38AM
(Associated Press Finance)
10:35AM
10:22AM
10:05AM
10:00AM
09:58AM
(The Wall Street Journal)
09:45AM
(Associated Press Finance)
09:30AM
09:12AM
08:39AM
08:36AM
08:17AM
08:17AM
(Investor's Business Daily)
08:15AM
08:06AM
08:00AM
07:53AM
07:37AM
07:35AM
07:20AM
07:04AM
(The Wall Street Journal)
07:03AM
(Associated Press Finance)
Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Dolsten Mikael Former Officer May 23 '25 Proposed Sale 23.09 59,781 1,380,632 May 23 10:54 AM Dolsten Mikael Former Officer May 05 '25 Proposed Sale 23.87 55,000 1,312,736 May 05 04:45 PM DAMICO JENNIFER B. SVP & Controller Mar 04 '25 Sale 25.93 2,500 64,825 11,850 Mar 06 01:57 PM DAMICO JENNIFER B. SVP & Controller Feb 27 '25 Option Exercise 31.31 22,416 701,845 31,063 Mar 03 05:39 PM SUSMAN SALLY Executive Vice President Feb 27 '25 Option Exercise 31.31 85,182 2,667,048 250,866 Mar 03 05:38 PM SAHNI PAYAL Executive Vice President Feb 27 '25 Option Exercise 31.31 19,054 596,581 44,242 Mar 03 05:38 PM McDermott Michael Executive Vice President Feb 27 '25 Option Exercise 31.31 48,419 1,515,999 122,413 Mar 03 05:37 PM LANKLER DOUGLAS M Executive Vice President Feb 27 '25 Option Exercise 31.31 156,914 4,912,977 309,790 Mar 03 05:37 PM Fonseca Lidia Executive Vice President Feb 27 '25 Option Exercise 31.31 72,629 2,274,014 111,534 Mar 03 05:36 PM BOURLA ALBERT Chairman & CEO Feb 27 '25 Option Exercise 31.31 582,823 18,248,188 931,744 Mar 03 05:36 PM McDermott Michael Executive Vice President Feb 22 '25 Option Exercise 30.17 11,125 335,641 87,636 Feb 25 07:38 PM DAMICO JENNIFER B. SVP & Controller Feb 22 '25 Option Exercise 30.17 8,741 263,716 17,602 Feb 25 07:38 PM BOURLA ALBERT Chairman & CEO Feb 22 '25 Option Exercise 30.17 238,399 7,192,498 570,436 Feb 25 07:06 PM LANKLER DOUGLAS M Executive Vice President Feb 22 '25 Option Exercise 30.17 85,824 2,589,310 232,775 Feb 25 07:05 PM SAHNI PAYAL Executive Vice President Feb 22 '25 Option Exercise 30.17 12,714 383,581 37,099 Feb 25 07:04 PM SUSMAN SALLY Executive Vice President Feb 22 '25 Option Exercise 30.17 63,573 1,917,997 225,184 Feb 25 07:02 PM BOSHOFF CHRISTOFFEL President, R&D Feb 22 '25 Option Exercise 30.17 8,741 263,716 159,085 Feb 25 06:58 PM BLAYLOCK RONALD E Director Feb 13 '25 Buy 25.65 19,457 499,072 27,707 Feb 14 05:16 PM